MedPharm and Mosanna collaboration to develop novel Metabolic Obstructive Sleep Apnea treatment
A collaboration between development and manufacturing services company MedPharm and biotech company Mosanna aims to develop and deliver a nasal spray treatment for a form of sleep apnea.
Contract topical and transdermal formulation development and manufacturing services company MedPharm (Guildford, UK) have announced their collaboration with Swiss biotech company Mosanna Therapeutics for the development of a nasal spray treatment for Metabolic Obstructive Sleep Apnea (MOSA).
MOSA occurs from the collapsing of the airway during sleep, affecting up to 1 billion individuals worldwide. Adverse metabolic and cardiovascular events are associated with both repeated partial and/or complete obstruction of the upper airway during sleep. This can often lead to a severe impact on the quality of life of those who suffer from the disease. Currently, continuous positive airway pressure (CPAP) is the most common method of treating MOSA. With up to 30% of patients not tolerating this form of treatment, these individuals have few pharmaceutical options available.
The development of the MOS-118 nasal spray by Mosanna functions by preventing airway collapse during sleep. The collaboration of Mosanna with MedPharm aims at precisely engineering a product that can deliver MOS-118 in a nasal spray form, acting locally in the upper airway overnight. Proprietary nasal testing models from MEdPharm will optimize the formulation and delivery of the product into the nasal cavitiy.
MedPharm President and CEO, Eugene Ciolgi, commented on the collaboration: “MedPharm’s primary mission is to support the development of life-changing therapeutics, and Mosanna’s nasal spray is a promising opportunity to do just that. We are excited to work with their team of experienced industry leaders to realise MOS-118's potential with the end goal of imrpoving the quality of life for those living with Metabolit Obstructive Sleep Apnea.”
Jonathan Talbot, CEO of Mosanna, added: “MedPharm is world-renowned for its dermal and transdermal capabilities including intranasal delivery routes, so [it] was a clear first choice for this project. I am also excited by the potential this partnership creates for additional projects on the horizon for Mosanna.”
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance